{
  "topics": [
    {
      "id": "topic-1",
      "name": "Canine lymphoma staging and substage impact",
      "mastery": 20
    },
    {
      "id": "topic-2",
      "name": "Osteosarcoma adjuvant chemotherapy decisions",
      "mastery": 20
    }
  ],
  "quizBank": [
    {
      "id": "q-1",
      "topicId": "topic-1",
      "difficulty": "intern",
      "type": "mcq",
      "question": "Which stage generally indicates bone marrow involvement in lymphoma staging systems?",
      "options": [
        "Stage III",
        "Stage IV",
        "Stage V",
        "Stage I"
      ],
      "answer": "Stage V",
      "explanation": "Stage V generally includes bone marrow, blood, or other non-lymphoid organ involvement.",
      "rationale": "Stage V generally includes bone marrow, blood, or other non-lymphoid organ involvement.",
      "commonMistake": "Selecting an answer without integrating staging/prognostic context."
    },
    {
      "id": "q-2",
      "topicId": "topic-1",
      "difficulty": "intern",
      "type": "short",
      "question": "List two common dose-limiting toxicities to monitor during CHOP-like protocols.",
      "answerKeywords": [
        "neutropenia",
        "gastrointestinal toxicity",
        "thrombocytopenia",
        "febrile neutropenia"
      ],
      "modelAnswer": "neutropenia, gastrointestinal toxicity, thrombocytopenia, febrile neutropenia",
      "explanation": "Hematologic and GI toxicities are commonly monitored and can drive dose adjustments.",
      "rationale": "Hematologic and GI toxicities are commonly monitored and can drive dose adjustments.",
      "commonMistake": "Providing generic points without case-linked prioritization."
    }
  ],
  "cases": [
    {
      "id": "case-1",
      "title": "Canine osteosarcoma post-amputation review",
      "template": [
        "Histologic grade and margins",
        "Thoracic staging findings",
        "Adjuvant chemo protocol choice",
        "Monitoring plan and owner communication"
      ]
    }
  ]
}